Activation and inhibition of various immunological effector mechanisms by circulating and intraarticular immune complexes is thought to explain many of the pathological manifestations of rheumatoid arthritis (RA).1 Consequently it is hoped that sensitive and simple techniques for measuring these complexes might be of value in the diagnosis of this disease and in assessing disease activity and monitoring treatment response. A recent study involving 18 different assays for immune complexes showed that the 2 assays giving the best discrimination between RA patients and controls were the Clq binding assay (Clq BA) and the monoclonal rheumatoid factor (MCRF) assay.2 Furthermore, Zubler et al.3
and Luthra et al.4 using these assays have shown high levels of immune-complex-like material in rheumatoid sera and synovial fluid and have correlated serum levels with some indices of disease activity.
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In this communication we describe our experience with these 2 assays in a comparative study of a group of 42 patients with RA. Our aim has been (1) to find if these assays correlate with the disease activity and with other variables of the rheumatoid process, and (2) to compare these assays to find if they are measuring similar immune-complex-like material in sera and synovial fluid.
Materials and methods

PATIENTS AND CONTROLS
Forty-two patients with definite or probable RA (American Rheumatism Association criteria) were selected from the rheumatological ward (19 patients) and the outpatient clinic (23 patients). Twenty-five of the patients were female and 17 male, the mean age was 52 years (range years), and the mean duration of the illness was 13 years (range 2 months to 27 years). Twenty-nine of the patients were seropositive, defined as a Rose-Waaler titre of >1:32.
The patients were divided into 3 groups: (1) those with active disease, defined by the presence of joint swelling, tenderness, and pain in one or more joints (15 patients); (2) those with active disease complicated by rheumatoid vasculitis defined by the presence (within 1 month of testing) of mononeuritis multiplex, a necrotising vasculitis, or the presence of skin ulceration not attributable to other causes (6 patients); and (3) those with inactive or suppressed disease defined by the absence of active joint inflammation (11 patients). Thirty-five of the patients were taking nonsteroidal anti-inflammatory drugs, 14 were taking low-dose prednisolone, 8 were taking penicillamine, 6 were on gold, 6 were taking antimalarials, and 1 was taking azathioprine. Three patients were taking no drugs. Control sera were obtained from healthy blood donors.
Venous blood was allowed to clot at room temperature, and serum, obtained within 4 hours, was divided into aliquots and stored at -800C. Joint fluid was aspirated from the knees in 10 patients, divided into aliquots, and stored at -800C.
C1Q BINDING ASSAY
The method used was that described by Zubler et al. (Table 2 ).
Ultracentrifugation studies (Fig. 3) . Ultracentrifugal analysis of 28 RA sera and 7 paired synovial fluids was performed, and a typical optical density and Clq binding profile is shown in Fig. 3 . In general, 3 Clq binding peaks were ob;erved, a high molecular weight peak, a peak sedimenting in the region a little heavier than IgG, and a lighter peak. This latter peak tended to be variable and in some a, (Fig. 4) . Only 2 of 232 blood donors had a binding greater than 10 tg/ml of HAGG equivalents, and this value was therefore taken as an upper normal limit. Twenty-four of the 42 RA patients (57 %) had an MCRF binding greater than this upper limit, and those patients with active disease had significantly more MCRF binding (P<0 05) than those with inactive disease. Five of the 6 patients with rheumatoid vasculitis had raised levels. A significant correlation was found between MCRF binding and the serum IgG but not with other clinical and laboratory variables (Table 3) .
Synovial fluid (Fig. 5) . Five of the 10 synovial fluids had raised MCRF binding with the mean synovial fluid MCRF binding (32 ,ug/ml HAGG equivalents) being higher than that of the corresponding serum (25 ,ug/ml HAGG equivalents).
This difference was not significant. MCRF binding in synovial fluid correlated significantly with MCRF binding in serum and with IgG and Clq binding in synovial fluid (Table 4 ).
Ultracentrifugation studies. (Fig. 6) . Ultracentrifugal analysis of MCRF binding in RA sera has been previously described.5 A further 4 sera and 2 synovial fluids were analysed in the present study. MCRF binding in all 4 sedimenting with uncomplexed native IgG (as previously described). However, in the 2 synovial fluids MCRF binding occurred both in the region sedimenting between the IgM and IgG markers and also in the IgG region (Fig. 6 ). This suggested that MCRF was binding with IgG-containing intermediate complexes present in the synovial fluid but not in the corresponding serum.
Discussion
We have compared the Clq binding assay and a nephelometric MCRF assay to other clinical and laboratory variables in assessing the serum and synovial fluid from a group of 42 patients with RA.
The Clq binding assay in RA has been extensively studied by Zubler and colleagues.3 This group found that the Clq binding was raised in the serum and synovial fluid of 66% and 76% respectively of RA patients when compared with patients with degenerative and post-traumatic joint diseases. In addition they found a significant correlation between serum Clq binding and disease activity as measured by a joint score, duration of morning stiffness, and the sedimentation rate. In the present study we have confirmed the high incidence of Clq binding in RA, particularly in those patients with active disease, and have noted high levels of Clq binding in all patients with rheumatoid vasculitis. This latter observation suggests that the Clq BA may be of value in detecting those patients at risk of developing this complication. However, in contrast to Zubler and colleagues we have found a significant correlation between Clq binding and the rheumatoid factor titre, and this observation has also been reported elsewhere.26 7 Indeed Erhardt et aL,6 using insolubilised IgG columns, found that Clq binding was associated with material with rheumatoid factor activity.
The material which binds Clq has been shown Both the Clq and MCRF assays in the present study were found to discriminate RA patients from healthy blood donors. Furthermore, from the significant correlations described it appears that the Clq binding assay was of some value in the assessment of the severity and activity of the rheumatoid process and appears to relate to the presence of extra-articular manifestations such as rheumatoid vasculitis. In addition, we have unpublished data suggesting that serial Clq measurement is of value in monitoring disease activity and response to treatment. In contrast, the value of the nephelometric MCRF assay is less clear. The results from the present study indicate that this assay has limited value in assessing disease activity and no value in detecting rheumatoid vasculitis, but this could be very dependent on the properties of the individual MCRF used. The technique is both simple and rapid, and therefore further comparative studies using different MCRFs are required, as these reagents may provide further insight into the nature and immunopathogenesis of RA. 
